Tiens Biotech Group, Inc. (TBV)

Tiens Biotech Group, Inc. conducts most of its business through two of its subsidiaries: Tianjin Tianshi Biological Development Co., Ltd., and Tiens Yihai Co., Ltd. Founded in 1998, Tianjin Tianshi focuses on researching, developing, manufacturing and marketing supplements and personal care products. Tiens Yihai on the other hand focuses on the research and development, production and marketing of nutrition supplements products, home care and personal care products.

Tiens’ herbal products, vitamin and mineral supplements and personal care products are sold in China as well as approximately 90 other countries. The company has significantly increased its revenue and earnings over the years by capitalizing on worldwide consumer demand for nutritional and wellness products. Tiens has positioned itself for further growth through product line enhancements and additional channels of distribution.

As a result of its ongoing R&D efforts, Tiens has developed, manufactured and marketed more than 20 major products and launches 5-to-7 new products each year. Attracting world-class talent to develop its high-quality products, Tiens has built modern research laboratories with superior scientific equipment and provides competitive compensation packages for the research staff. In addition to developing its own products, the company also plans to utilize product acquisitions to expand its product portfolio.

Currently, insiders hold 95.09% of the shares outstanding, which gives them great incentive to protect and build shareholder value. In addition to growing revenues and earnings at such a rapid and consistent rate, the management team has also proven their competence by providing Return on Equity (ROE) of 14.7%, Return on Assets of 11.4%, and Return on Capital of 14.2%. These returns are dramatically higher than the average percentages and speak volumes of the company’s effectiveness.

Key statistics (5/6/10):

Market cap: $155 Million
P/E Ratio: 6.6 versus industry average of 14.2
P/S Ratio: 2.56 versus industry average of 3.65
Price/Cash Flow Ratio: 5.8 versus industry average of 11.2

Debt/Equity Ratio: 0.00 versus industry average of 0.48
Current Ratio: 2.0 versus industry average of 2.7
Quick Ratio: 1.9 versus industry average of 1.9
Book Value/Share: $2.47 versus current market price of $2.17

Return on Equity: 14.7% versus industry average of 12.4%
Return on Assets: 11.4% versus industry average of 4.7%
Return on Capital: 14.2% versus industry average of 6.6%
5-Year average ROE: 20.8% versus industry average of 8.7%

Recent News